FIP1L1 and Chronic Eosinophilic Leukemia, Not Otherwise Specified: In vitro and in vivo study then confirmed that ponatinib is a potent inhibitor of CEL cells bearing wild-type (WT) or T674I FIP1L1-PDGFRα.